『3: Disappointing Data. Cosentyx Doesn’t Deliver in Giant Cell Arteritis』のカバーアート

3: Disappointing Data. Cosentyx Doesn’t Deliver in Giant Cell Arteritis

3: Disappointing Data. Cosentyx Doesn’t Deliver in Giant Cell Arteritis

無料で聴く

ポッドキャストの詳細を見る

このコンテンツについて

Novartis’ blockbuster Cosentyx has hit a wall. In this episode of The Biotech Brief, we unpack the Phase 3 GCAptAIN trial results, where Cosentyx failed to show benefit for patients with giant cell arteritis. We explore what GCA is, why this label expansion mattered, and how the drug—once seen as a contender in this space—fell short. Plus, we look at the commercial implications, the competitive IL-6 landscape, and what this means for the future of Cosentyx and Novartis’ inflammatory disease pipeline.

3: Disappointing Data. Cosentyx Doesn’t Deliver in Giant Cell Arteritisに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。